Rosenstock, J., Perkovic, V., Alexander, J. H., Cooper, M. E., Kahn, S. E., Marx, N., … Mcguire, D. K. (2017). CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk. In DIABETES (Vol. 66, pp. A344–A344). San Diego, CA: AMER DIABETES ASSOC.

Rosenstock, Julio, Vlado Perkovic, John H. Alexander, Mark Emmanuel Cooper, Steven E. Kahn, Nikolaus Marx, Michael J. Pencina, et al. “CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk.” In DIABETES, 66:A344–A344. AMER DIABETES ASSOC, 2017.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Kahn SE, Marx N, et al. CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk. In: DIABETES. AMER DIABETES ASSOC; 2017. p. A344–A344.

Rosenstock, Julio, et al. “CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk.” DIABETES, vol. 66, AMER DIABETES ASSOC, 2017, pp. A344–A344.

Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Kahn SE, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, George JT, Broedl UC, Woerle H-J, Von Eynatten M, Mcguire DK. CARMELINA (R) Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk. DIABETES. AMER DIABETES ASSOC; 2017. p. A344–A344.